Treatment
Dupilumab clinical trials
We’re tracking 52 recruiting studies that include Dupilumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06116526RecruitingPhase 4
Reducing Dupixent in kids with well-controlled eczema
This study looks at whether children with well-controlled eczema can safely reduce how often they take Dupixent. It aims to find the lowest effective dose to keep eczema under control.
Baltimore, MarylandAges 1–17 - NCT07091175RecruitingPhase 2
Dupilumab for nephrotic syndrome in children
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
Singapore, SingaporeAges 6–18 - NCT07587658RecruitingPhase 4
Dupilumab after a severe COPD flare-up
This study tests whether adding the drug dupilumab to usual hospital care for a severe COPD flare-up helps patients recover better than usual care alone. It is for adults with a specific type of inflammation in their blood, and may reduce the chance of future flare-ups.
Mullica Hill, New JerseyAges 40 years+ - NCT07612878Recruiting
Registry tracking COPD patients starting dupilumab treatment
This is a registry—an observational study tracking patients with COPD (chronic lung disease) who are newly starting a medication called dupilumab. Researchers will follow your health outcomes to learn how well this treatment works in real-world practice.
Indianapolis, IndianaAges 40 years+ - NCT07754786RecruitingPhase 3
Comparing a new eczema medicine with dupilumab
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
Guangzhou, GuangdongAges 18–75 - NCT05263206RecruitingPhase 3
Shot medicine (dupilumab) for severe, unexplained chronic itching
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
Bakersfield, CaliforniaAges 18–90 - NCT07783425RecruitingPhase 3
Treatment for moderate-to-severe eczema
This study tests a new medicine called Tilrekimig for people with moderate-to-severe eczema (also called atopic dermatitis) whose symptoms have not improved with creams or ointments. The goal is to see if this medicine helps reduce symptoms and improve skin condition.
Phoenix, ArizonaAges 12 years+ - NCT06665971RecruitingPhase 4
Dupilumab for esophagus muscle function in EoE
This trial tests if dupilumab, a weekly injection, can improve the muscle function of the esophagus in people with eosinophilic esophagitis (EoE) who haven't gotten better with acid-reducing medications. Researchers want to see if it helps with swallowing and reduces inflammation.
La Jolla, CaliforniaAges 22 years+ - NCT07467564Recruiting
Does Dupilumab help anxiety and depression in eczema?
This study looks at whether Dupilumab (a treatment for moderate-to-severe eczema) can also help improve symptoms of anxiety and depression. It is for people with eczema who also have these mood symptoms and are about to start Dupilumab.
DohaAges 12 years+ - NCT07309614RecruitingPhase 3
Dupilumab for asthma remission
This trial tests whether dupilumab, a medicine that helps reduce airway inflammation, can help people with asthma achieve remission. You may be eligible if you have asthma with high markers of inflammation and have had asthma attacks despite using your regular inhaler.
Nedlands, Western AustraliaAges 18–79 - NCT06705387RecruitingPhase 2
Dupilumab vs steroid for narrow EoE in young people
This study compares two treatments for EoE that has caused narrowing in the esophagus: dupilumab (a biologic injection) versus a topical corticosteroid (a swallowed steroid). It aims to see which works better for teens and young adults to improve swallowing and reduce inflammation.
Aurora, ColoradoAges 12–25 - NCT07276425Recruiting
Dupilumab for prurigo nodularis: long-term effects
This study follows people with moderate-to-severe prurigo nodularis who are starting dupilumab. It looks at how the medicine works over time and how it affects the immune system, to help understand long-term benefits.
Utrecht, UtrechtAges 18 years+ - NCT07277322RecruitingPhase 1/Phase 2
Two immunotherapy drugs before surgery for MSS colorectal cancer with liver spots
This trial tests a combination of two immunotherapy drugs (Dupilumab and Toripalimab) before surgery for people with MSS colorectal cancer that has spread to the liver. The goal is to see if this treatment can shrink the liver tumors and help the body's immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT07257835Recruiting
Dupilumab for tough stomach and gut diseases
This trial tests if dupilumab can help people with hard-to-treat stomach ulcers linked to eosinophilic gastrointestinal disorders (EGIDs), where a type of white blood cell builds up in the gut. It may offer a new option for those who haven't gotten better with other treatments.
ShanghaiAges 1–18 - NCT05094570RecruitingPhase 4
Dupilumab for nasal polyps with staph bacteria
This trial studies whether dupilumab (an injection) can reduce staph bacteria in the nose and make the nose’s microbes more diverse in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). If you already have a plan to start dupilumab as standard care, the study may help doctors better understand why it works.
Charlottesville, VirginiaAges 18–65 - NCT06398873Recruiting
Dupilumab and nasal lining in chronic sinusitis with polyps
This study tests whether dupilumab, a medication given as an injection, helps improve the lining of the nose in people with chronic sinus inflammation and nasal polyps. If you have nasal polyps and are about to start dupilumab, or if you have sinusitis without polyps, you may be eligible to join.
Vienna, AustriaAges 18–99 - NCT07112378RecruitingPhase 3
Study of dupilumab for young children with eosinophilic esophagitis
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
Phoenix, ArizonaAges 6 months–6 years - NCT07052396Recruiting
Dupilumab for COPD: long-term real-world study
This study looks at how well dupilumab works over time for people with COPD who still have symptoms despite standard treatments and who have a certain type of inflammation (elevated eosinophils). It uses data from regular doctor visits and patient questionnaires to understand real-world benefits and safety.
AuerbachAges 18 years+ - NCT07053423RecruitingPhase 4
Dupilumab for COPD with airway inflammation
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
Birmingham, AlabamaAges 40–85 - NCT06892704Recruiting
Dupilumab smell restoration study for CRSwNP
This study tests if the medication dupilumab can improve smell loss in people with chronic sinusitis and nasal polyps. Researchers will check if blocking in the nose and electrical signals in the brain can predict who will benefit.
Chicago, IllinoisAges 18–65 - NCT06851403Enrolling by invitation
Dupilumab for children with asthma in China
This study looks at how well and how safely the medicine Dupilumab works for children whose asthma is not well-controlled with their current inhalers. The goal is to see if it can help reduce asthma attacks and improve daily life.
Guangzhou, GuangdongAges 4–16 - NCT06818019RecruitingPhase 4
Stopping dupilumab when asthma is well controlled
This study tests whether it’s safe to stop taking dupilumab once your severe asthma has been well controlled for a long time. If you join, you may stop the medication and be closely monitored to see if your asthma stays under control.
Toulouse, CHU de ToulouseAges 18 years+ - NCT06743581Recruiting
Cemiplimab and dupilumab before lung cancer surgery
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
Montreal, QuebecAges 18 years+ - NCT06695897Recruiting
Long-term real-world study of Dupilumab for eosinophilic esophagitis
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
Aschaffenburg, BavariaAges 12 years+
What Dupilumab is being studied for
Conditions with recruiting Dupilumab studies.
Common questions
- Are there clinical trials studying Dupilumab?
- Yes. Clin2 currently lists 52 recruiting studies that include Dupilumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dupilumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dupilumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dupilumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.